Adult

Pivmecillinam

Warning

General Information

A penicillin antibiotic. Do NOT use if patient is allergic to penicillin.

Restricted formulary antimicrobial: For details see OUH netFormulary

 

AWaRe antibiotic classification: 'Access'. Use as per guidelines.

Standard dose

400mg po STAT then 8 hours later 200mg tds

 

Obesity

No dose adjustment required

Renal and hepatic impairment

Renal impairment

Dose adjustment is not necessary in impaired renal function.

If using for extended periods of time: Accumulation may occur in patients with severe renal impairment. Discuss with Micro/ID about the need to use a lower dose.

 

Hepatic impairment

Dose adjustment not necessary

Notable interactions

Methotrexate: Pivmecillinam can reduce excretion of methotrexate (increased risk of toxicity).

Valproic acid, valproate or other medication liberating pivalic acid: Avoid concurrent use due to increased risk of carnitine depletion.

Vitamin K antagonists: Appropriate monitoring should be undertaken. It would be prudent to monitor coagulation status within 3 days of starting or stopping a penicillin.

This is not a complete list. Please see the BNF, Summary of Product Characteristics or speak to a pharmacist.

Pregnancy and breastfeeding

Pregnancy 

Discuss with pharmacy

 

Breastfeeding 

Safe. Mecillinam is excreted in human milk, but at therapeutic doses of Pivmecillinam no effects on the breast-fed newborns/infants are anticipated. Pivmecillinam can be used during breast-feeding.

Additional information

Pivmecillinam contra-indications include patients with:

  • any condition resulting in impaired transit through the oesophagus (e.g. gastro-intestinal obstruction or oesophageal strictures)
  • genetic metabolism anomalies known to be leading to severe carnitine deficiency, such as carnitine transporter defect, methylmalonic aciduria or propionic acidaemia.

This is not a complete list. Please see the BNF, SPC or speak to a pharmacist.

Pivmecillinam should be used with caution in patients with porphyria since pivmecillinam has been associated with acute attacks of porphyria.

The intake of pivmecillinam shortly before delivery may cause a false positive test for isovaleric acidemia in the newborn as part of neonatal screening. 

References

Editorial Information

Next review date: 02 Nov 2026